Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Published:2017-03 Issue:3 Volume:18 Page:312-322
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Sharma Padmanee,Retz Margitta,Siefker-Radtke Arlene,Baron Ari,Necchi Andrea,Bedke Jens,Plimack Elizabeth R,Vaena Daniel,Grimm Marc-Oliver,Bracarda Sergio,Arranz José Ángel,Pal Sumanta,Ohyama Chikara,Saci Abdel,Qu Xiaotao,Lambert Alexandre,Krishnan Suba,Azrilevich Alex,Galsky Matthew D

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987;Bellmunt;J Clin Oncol,2012

2. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;Von der Maase;J Clin Oncol,2000

3. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer;Sonpavde;Clin Genitourin Cancer,2014

4. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

5. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder;Ortmann;Future Oncol,2013

Cited by 1402 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic effect of cancer therapy;Metabolomics of Bladder Cancer;2025

2. Contribution of metabolomics in the discovery of biomarker for urinary bladder cancer;Metabolomics of Bladder Cancer;2025

3. Bladder Cancer;International Encyclopedia of Public Health;2025

4. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10

5. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin;Journal of Medical Economics;2024-09-11